The mission of the Greenville SC CCOP (GCCOP) is to make contributions to the National Cancer Institutes'goal of """"""""eliminating suffering and death from cancer"""""""" through NCI research trial participation. GCCOP will increase awareness and involvement of community physicians and patients in clinical trials;increase our segment of participants to include the underserved and minorities;and will accelerate the transfer of knowledge gained through research to the community The objectives of GCCOP are the following: 1. To enroll eligible subjects to NCI trials including treatment, prevention and supportive care. 2. To assure protocol compliance and accurate, timely data submissions. 3. To conduct research by engaging the community, inclusive of minorities and the underserved, and informing the community of advances made through research. Cancer patients suffer due to their disease as well as their treatment. GCCOP's broad goal is to contribute to research outcomes so that death, pain and suffering are reduced in oncology patients. GCCOP will achieve this goal by following specific procedures to protect, enroll and report on our research patients. To meet these goals the research team, consisting of a core group of investigators and a dedicated research staff, have developed a defined process to ethically consent and treat research subjects. Standard operating procedures and quality assurance procedures provide guidance to ensure the subject is eligible, treated according to the protocol and accurately reported.
The NCI assesses the incorporation of state of the art treatment for cancer patients throughout the nation. Through research, state of the art treatments are determined, and the information disseminated to clinical practioners. GCCOP's participation in NCI research contributes to improve the care of cancer patients.
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8|
|Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
Showing the most recent 10 out of 95 publications